Dr. Jayson Parker is a Lecturer in the Master of Biotechnology Program and the Institute for Biomaterials and Biomedical Engineering at the University of Toronto. His appointment is in the faculty of Biology. His main research interest is in risk assessment of clinical trial design in diverse disease areas. Dr. Parker's teaching interests include clinical trial design, patents, off-label drug use, biologic therapies, medical marketing, implantable medical devices and therapeutic safety. He is also currently a medical/scientific advisor to the hedge fund Burlington Capital Inc, which has a 100 million in assets under management. Most recently, he was a medical liaison for Schering Plough’s biologic infliximab (Remicade) and for Novo Nordisk’s biologic rfVIIa (Novoseven/Niastase). He has been a “buy side” stock analyst covering the life sciences for Investor’s Group and the Director of Medical Science Equities at AIC limited, both prominent mutual fund companies. His research experience includes brain imaging of Alzheimer’s disease (Sunnybrook hospital), animal models of alcohol abuse (Addiction Research Foundation) and animal models of schizophrenia (University of Toronto). His Doctoral work was on brain trauma (sensory map plasticity) and his Master’s research on cocaine addiction (reward pathways). During his MBA he focused on competitive intelligence issues in biotechnology.
